Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer

Autor: K Fishwick, E R Plumner, M J Griffin, Martin Highley, J G Wright, Alan V. Boddy, Huw D. Thomas, J Sludden, A H Calvert

Publikováno v: Cancer Chemotherapy and Pharmacology. 48:15-21

Purpose: To determine the effect on systemic pharmacology and clinical toxicity of dose and mode of administration of paclitaxel combined with carboplatin in the treatment of ovarian cancer. Patients and methods: A total of 18 patients were treated w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::583f583db3f84f7ffde9040f23c99f21
https://doi.org/10.1007/s002800100295

Zobrazit plný text záznamu

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion

Autor: J. Sludden, P. Wissel, D DeMaria, Chris Twelves, Stan B. Kaye, A. McDonald, Peter J. O'Dwyer, Louise B. Grochow, James P. Stevenson, K. Selinger, L. Paz-Ares

Publikováno v: Annals of Oncology. 10:339-344

Summary Background Preclinical results support a prolonged schedule of administration for topoisomerase I inhibitors, and we have previously demonstrated the safety and activity of the novel water-soluble topoisomerase I inhibitor GG211 when given as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445bf46949a3018f384586c0876248f2
https://doi.org/10.1023/a:1008313011289

Zobrazit plný text záznamu

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee

Autor: C J, Twelves, C, Gardner, A, Flavin, J, Sludden, I, Dennis, J, de Bono, P, Beale, P, Vasey, C, Hutchison, M A, Macham, A, Rodriguez, I, Judson, N M, Bleehen

Publikováno v: British Journal of Cancer

DACA, also known as XR5000, is an acridine derivative active against both topoisomerase I and II. In this phase I study, DACA was given as a 3-h intravenous infusion on 3 successive days, repeated every 3 weeks. A total of 41 patients were treated at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3964f5042c44c7c3ad104a82a8cc7bfd
https://pubmed.ncbi.nlm.nih.gov/10468297

Zobrazit plný text záznamu

The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations

Autor: Stuart C. Pritchard, D. A. Collier, Elaina Susan Renata Collie-Duguid, Howard L. McLeod, Tao Li, J. Sludden, Robert H. Powrie

Publikováno v: Pharmacogenetics. 9(1)

Thiopurine methyltransferase metabolizes 6-mercaptopurine, thioguanine and azathioprine, thereby regulating cytotoxicity and clinical response to these thiopurine drugs. In healthy Caucasian populations, 89-94% of individuals have high thiopurine met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d224276d0582e7b20fdc72f14ced6f7
https://pubmed.ncbi.nlm.nih.gov/10208641

Zobrazit plný text záznamu

Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals

Autor: H L, McLeod, A C, Syvänen, J, Githang'a, A, Indalo, D, Ismail, K, Dewar, I, Ulmanen, J, Sludden

Publikováno v: Pharmacogenetics. 8(3)

Catechol O-methyltransferase (COMT) inactivates neurotransmitters, hormones and drugs such as levodopa. COMT activity is inherited in an autosomal recessive manner and individuals with low activity have thermolabile COMT protein. A low activity allel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7716a670e5c39ccf16f85af2341356b4
https://pubmed.ncbi.nlm.nih.gov/9682265

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Intraperitoneal carboplatin in icodextrin 4% as first-line treatment for epithelial ovarian cancer: A phase I/II trial

Autor: J. Sludden, D. R. Ferry, D. J. Murphy, A. V. Boddy, L. Hofman

Publikováno v: Journal of Clinical Oncology. 25:5522-5522

5522 Background: First line intraperitoneal (IP) chemotherapy improves survival in epithelial ovarian cancer (EOC). Problems with IP delivery are not uncommon; in the GOG 172 study, 34% of patients discontinued IP therapy due to catheter complication

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9aed39fb795e4eeadd98cd748dcc3cf
https://doi.org/10.1200/jco.2007.25.18_suppl.5522

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání